Publicaciones en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (22)

2023

  1. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

    Breast cancer research : BCR, Vol. 25, Núm. 1, pp. 2

2022

  1. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib

    npj Precision Oncology, Vol. 6, Núm. 1

  2. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 7, pp. 1383-1390

2021

  1. Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)

    Annals of Oncology

  2. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

    Annals of Oncology, Vol. 32, Núm. 8, pp. 1015-1024

2020

  1. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 1, pp. 60-72

  2. Biomarker analyses of response to cyclin-dependent kinase 4/6 inhibition and endocrine therapy in women with treatment-naïve metastatic breast cancer

    Clinical Cancer Research, Vol. 26, Núm. 1, pp. 110-121

  3. Oncological care organisation during COVID-19 outbreak

    ESMO Open, Vol. 5, Núm. 4

  4. Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy

    JNCI Cancer Spectrum, Vol. 4, Núm. 1

  5. Overall survival with ribociclib plus fulvestrant in advanced breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 6, pp. 514-524

  6. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2

    Clinical Breast Cancer, Vol. 20, Núm. 2, pp. e173-e180

2019

  1. Assessment of ERBB2 / HER2 Status in HER2 -Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

    JAMA Oncology, Vol. 5, Núm. 3, pp. 366-375

  2. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study

    Journal of Clinical Oncology

2018

  1. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

    Annals of Oncology, Vol. 29, Núm. 3, pp. 669-680

  2. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 1, pp. 115-126

2016

  1. HER2 gene amplification testing by fluorescent in situ hybridization (FISH): Comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in Breast Cancer International Research Group clinical trials

    Journal of Clinical Oncology, Vol. 34, Núm. 29, pp. 3518-3528

  2. Palbociclib and letrozole in advanced breast cancer

    New England Journal of Medicine, Vol. 375, Núm. 20, pp. 1925-1936

2015

  1. PTEN loss is associated with worse outcome in HER2-Amplified breast cancer patients but is not associated with trastuzumab resistance

    Clinical Cancer Research, Vol. 21, Núm. 9, pp. 2065-2074

2013

  1. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study

    Oncologist, Vol. 18, Núm. 7, pp. 812-818

2011

  1. Adjuvant trastuzumab in HER2-positive breast cancer.

    The New England journal of medicine, Vol. 365, Núm. 14, pp. 1273-1283